Status:
RECRUITING
Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
Ischemic Stroke
Transient Ischemic Attack (TIA)
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study will conduct a cluster randomized controlled trial to Evaluate whether the Intelligent Lipid Management Decision-support System can increase the proportion of patients 1-year target achieve...
Detailed Description
Large scale randomized trials and systematic reviews have established the efficacy of lipid lowering therapy for acute ischemic stroke. However, adherence to these evidence-based performance measures ...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Age≥18 years as of the screening date;
- Patients with non-cardioembolic ischemic stroke or TIA within 3 months prior to the screening date;
- Prescribed Evolocumab at physician's discretion;
- Signed informed consent.
- Exclusion Criteria:
- Intracranial hemorrhagic diseases: such as cerebral hemorrhage, subarachnoid hemorrhage, etc.;
- Patients confirmed by baseline head CT or MRI to have hemorrhage or other pathological brain diseases, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis);
- Silent cerebral infarction without signs and symptoms;
- Participation in a clinical trial of another drug or device in the past 3 months or ongoing at the time of the screening date;
- Any prior use of Evolocumab or other PCSK9 inhibitor treatments within the past 6 months prior to the screening date;
- Life expectancy \<12 months or unable to complete the research for other reasons as of the screening date;
- Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders;
- Refusal to participate in the enrollment survey.
Exclusion
Key Trial Info
Start Date :
November 3 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2028
Estimated Enrollment :
4000 Patients enrolled
Trial Details
Trial ID
NCT07143149
Start Date
November 3 2025
End Date
March 31 2028
Last Update
January 2 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tiantan Hospital
Beijing, China